Wong, Harvey

Discovery of a Potent Small-Molecule Antagonist of Inhibitor of Apoptosis (IAP) Proteins and Clinical Candidate for the Treatment of Cancer (GDC-0152)

Flygare, J. A., Beresini, M., Budha, N., Chan, H., Chan, I. T., Cheeti, S., Cohen, F., Deshayes, K., Doerner, K., Eckhardt, S. G., et al. (2012) · Journal of Medicinal Chemistry

Cell death mechanisms and regulationHeterocyclic Compound Synthesis and Bioactivity

Cited by 252

Antitumor activity of targeted and cytotoxic agents in murine subcutaneous tumor models correlates with clinical response

Wong, H., Choo, E. F., Alicke, B., Ding, X., La, H., McNamara, E., Theil, F.-P., Tibbitts, J., Friedman, L. S., Hop, C. E. C. A., et al. (2012) · Clinical Cancer Research

Mathematical Biology Tumor GrowthStatistical Methods in Clinical Trials

Cited by 133

Physiologically based pharmacokinetic models of small molecules and therapeutic antibodies: a mini‐review on fundamental concepts and applications

Ferl, G. Z., Theil, F., & Wong, H. (2016) · Biopharmaceutics & Drug Disposition

Monoclonal and Polyclonal Antibodies ResearchPharmaceutical studies and practices

Cited by 54

A Phase I Dose-Escalation Study Evaluating the Safety Tolerability and Pharmacokinetics of CUDC-427, a Potent, Oral, Monovalent IAP Antagonist, in Patients with Refractory Solid Tumors

Tolcher, A. W., Bendell, J. C., Papadopoulos, K. P., Burris, H. A., Patnaik, A., Fairbrother, W. J., Wong, H., Budha, N., Darbonne, W. C., Peale, F., et al. (2016) · Clinical Cancer Research

Cell death mechanisms and regulationCancer-related Molecular Pathways

Cited by 33

Translational pharmacokinetic-pharmacodynamic analysis in the pharmaceutical industry: an IQ Consortium PK-PD Discussion Group perspective

Wong, H., Bohnert, T., Damian-Iordache, V., Gibson, C., Hsu, C.-P., Krishnatry, A. S., Liederer, B. M., Lin, J., Lu, Q., Mettetal, J. T., et al. (2017) · Drug Discovery Today

Statistical Methods in Clinical TrialsPharmaceutical studies and practices

Cited by 27